Predictive Oncology (NASDAQ: POAI), a data and
artificial-intelligence- (“AI”) driven, discovery-services company, today
announced that it has signed a letter of intent (“LOI”) to acquire Quantitative
Medicine (“QM”), a biomedical analytics and computational biology company. By
combining QM’s CoRE predictive modeling platform with POAI’s tumor profiling
proficiency and data, company management believes the acquisition will assist
in fast-tracking the commercialization of its AI-driven technology and
services. Subject to the negotiation of a definitive agreement and other terms
and conditions, the transaction is anticipated to be completed within the first
two quarters of 2020. “Our goal is to provide researchers in pharma, biopharma
and diagnostic companies’ with actionable insights that will not only drive the
development of new precision therapies, companion diagnostics, and biomarkers,
but will also help them design better targeted trials,” Predictive Oncology
president and CEO Dr. Carl Schwartz stated in the news release. “Working
together, we have the potential to dramatically improve patient outcomes.”
To view the full press release, visit http://ibn.fm/uIAbM
About Predictive Oncology
POAI is bringing precision medicine, or tailored medical
treatment using the individual characteristics of each patient, to the
treatment of cancer. Through its Helomics division, the company leverages its
unique, clinically validated patient-derived (PDx) smart tumor profiling
platform to provide oncologists with a roadmap to help individualize therapy.
In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases to build AI-driven models of
tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
